vs
BILL Holdings, Inc.（BILL）与Revvity（RVTY）财务数据对比。点击上方公司名可切换其他公司
Revvity的季度营收约是BILL Holdings, Inc.的1.9倍（$772.1M vs $414.7M），Revvity净利率更高（12.7% vs -0.6%，领先13.4%），BILL Holdings, Inc.同比增速更快（14.4% vs 5.9%），Revvity自由现金流更多（$161.8M vs $103.8M），过去两年BILL Holdings, Inc.的营收复合增速更高（13.3% vs 9.0%）
BILL Holdings, Inc. 是总部位于美国加利福尼亚州圣何塞的企业，专注为美国小型企业提供自动化云原生财务运营软件。旗下Bill.com Connect是白标端到端支付自动化平台，可供金融机构接入其单点登录的线上企业银行生态中使用。
Revvity是一家美国生命科学与诊断领域企业，主要服务制药、生物技术行业客户，重点围绕细胞治疗、基因治疗等前沿技术领域提供相关产品与解决方案，其前身为业务布局多元的老牌企业珀金埃尔默。
BILL vs RVTY — 直观对比
营收规模更大
RVTY
是对方的1.9倍
$414.7M
营收增速更快
BILL
高出8.5%
5.9%
净利率更高
RVTY
高出13.4%
-0.6%
自由现金流更多
RVTY
多$58.0M
$103.8M
两年增速更快
BILL
近两年复合增速
9.0%
损益表 — Q2 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $414.7M | $772.1M |
| 净利润 | $-2.6M | $98.4M |
| 毛利率 | 79.8% | — |
| 营业利润率 | -4.4% | 14.5% |
| 净利率 | -0.6% | 12.7% |
| 营收同比 | 14.4% | 5.9% |
| 净利润同比 | -107.7% | 3.9% |
| 每股收益（稀释后） | $-0.03 | $0.86 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收BILLRVTY
| Q4 25 | $414.7M | $772.1M | ||
| Q3 25 | $395.7M | $698.9M | ||
| Q2 25 | $383.3M | $720.3M | ||
| Q1 25 | $358.2M | $664.8M | ||
| Q4 24 | $362.6M | $729.4M | ||
| Q3 24 | $358.4M | $684.0M | ||
| Q2 24 | $343.7M | $691.7M | ||
| Q1 24 | $323.0M | $649.9M |
净利润BILLRVTY
| Q4 25 | $-2.6M | $98.4M | ||
| Q3 25 | $-3.0M | $46.7M | ||
| Q2 25 | $-7.1M | $53.9M | ||
| Q1 25 | $-11.6M | $42.2M | ||
| Q4 24 | $33.5M | $94.6M | ||
| Q3 24 | $8.9M | $94.4M | ||
| Q2 24 | $7.6M | $55.4M | ||
| Q1 24 | $31.8M | $26.0M |
毛利率BILLRVTY
| Q4 25 | 79.8% | — | ||
| Q3 25 | 80.5% | 53.6% | ||
| Q2 25 | 80.8% | 54.5% | ||
| Q1 25 | 81.2% | 56.5% | ||
| Q4 24 | 81.6% | — | ||
| Q3 24 | 82.0% | 56.3% | ||
| Q2 24 | 81.0% | 55.7% | ||
| Q1 24 | 83.0% | 54.6% |
营业利润率BILLRVTY
| Q4 25 | -4.4% | 14.5% | ||
| Q3 25 | -5.2% | 11.7% | ||
| Q2 25 | -5.8% | 12.6% | ||
| Q1 25 | -8.1% | 10.9% | ||
| Q4 24 | -6.0% | 16.3% | ||
| Q3 24 | -2.1% | 14.3% | ||
| Q2 24 | -6.5% | 12.4% | ||
| Q1 24 | -8.6% | 6.8% |
净利率BILLRVTY
| Q4 25 | -0.6% | 12.7% | ||
| Q3 25 | -0.7% | 6.7% | ||
| Q2 25 | -1.8% | 7.5% | ||
| Q1 25 | -3.2% | 6.4% | ||
| Q4 24 | 9.3% | 13.0% | ||
| Q3 24 | 2.5% | 13.8% | ||
| Q2 24 | 2.2% | 8.0% | ||
| Q1 24 | 9.8% | 4.0% |
每股收益（稀释后）BILLRVTY
| Q4 25 | $-0.03 | $0.86 | ||
| Q3 25 | $-0.03 | $0.40 | ||
| Q2 25 | $0.02 | $0.46 | ||
| Q1 25 | $-0.11 | $0.35 | ||
| Q4 24 | $-0.06 | $0.77 | ||
| Q3 24 | $0.08 | $0.77 | ||
| Q2 24 | $0.37 | $0.45 | ||
| Q1 24 | $0.00 | $0.21 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $1.1B | $919.9M |
| 总债务越低越好 | $1.8B | — |
| 股东权益账面价值 | $3.8B | $7.3B |
| 总资产 | $10.1B | $12.2B |
| 负债/权益比越低杠杆越低 | 0.48× | — |
8季度趋势，按日历期对齐
现金及短期投资BILLRVTY
| Q4 25 | $1.1B | $919.9M | ||
| Q3 25 | $1.1B | $931.4M | ||
| Q2 25 | $1.0B | $991.8M | ||
| Q1 25 | $1.0B | $1.1B | ||
| Q4 24 | $1.6B | $1.2B | ||
| Q3 24 | $853.5M | $1.2B | ||
| Q2 24 | $985.9M | $2.0B | ||
| Q1 24 | $952.5M | $1.7B |
总债务BILLRVTY
| Q4 25 | $1.8B | — | ||
| Q3 25 | $1.9B | — | ||
| Q2 25 | $1.7B | — | ||
| Q1 25 | $1.7B | — | ||
| Q4 24 | $1.7B | — | ||
| Q3 24 | $914.8M | — | ||
| Q2 24 | $914.0M | — | ||
| Q1 24 | $1.1B | — |
股东权益BILLRVTY
| Q4 25 | $3.8B | $7.3B | ||
| Q3 25 | $3.9B | $7.4B | ||
| Q2 25 | $3.9B | $7.6B | ||
| Q1 25 | $3.9B | $7.6B | ||
| Q4 24 | $3.8B | $7.7B | ||
| Q3 24 | $4.0B | $7.9B | ||
| Q2 24 | $4.1B | $7.9B | ||
| Q1 24 | $4.1B | $7.8B |
总资产BILLRVTY
| Q4 25 | $10.1B | $12.2B | ||
| Q3 25 | $10.2B | $12.1B | ||
| Q2 25 | $10.1B | $12.4B | ||
| Q1 25 | $9.6B | $12.4B | ||
| Q4 24 | $9.7B | $12.4B | ||
| Q3 24 | $9.0B | $12.8B | ||
| Q2 24 | $9.2B | $13.4B | ||
| Q1 24 | $9.1B | $13.4B |
负债/权益比BILLRVTY
| Q4 25 | 0.48× | — | ||
| Q3 25 | 0.48× | — | ||
| Q2 25 | 0.44× | — | ||
| Q1 25 | 0.43× | — | ||
| Q4 24 | 0.44× | — | ||
| Q3 24 | 0.23× | — | ||
| Q2 24 | 0.22× | — | ||
| Q1 24 | 0.28× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $105.3M | $182.0M |
| 自由现金流经营现金流 - 资本支出 | $103.8M | $161.8M |
| 自由现金流率自由现金流/营收 | 25.0% | 21.0% |
| 资本支出强度资本支出/营收 | 0.4% | 2.6% |
| 现金转化率经营现金流/净利润 | — | 1.85× |
| 过去12个月自由现金流最近4个季度 | $378.8M | $509.4M |
8季度趋势，按日历期对齐
经营现金流BILLRVTY
| Q4 25 | $105.3M | $182.0M | ||
| Q3 25 | $96.9M | $138.5M | ||
| Q2 25 | $83.8M | $134.3M | ||
| Q1 25 | $99.5M | $128.2M | ||
| Q4 24 | $78.7M | $174.2M | ||
| Q3 24 | $88.6M | $147.9M | ||
| Q2 24 | $78.6M | $158.6M | ||
| Q1 24 | $66.8M | $147.6M |
自由现金流BILLRVTY
| Q4 25 | $103.8M | $161.8M | ||
| Q3 25 | $95.6M | $120.0M | ||
| Q2 25 | $81.0M | $115.5M | ||
| Q1 25 | $98.4M | $112.2M | ||
| Q4 24 | $78.3M | $149.8M | ||
| Q3 24 | $88.6M | $125.6M | ||
| Q2 24 | $78.4M | $136.6M | ||
| Q1 24 | $66.8M | $129.7M |
自由现金流率BILLRVTY
| Q4 25 | 25.0% | 21.0% | ||
| Q3 25 | 24.1% | 17.2% | ||
| Q2 25 | 21.1% | 16.0% | ||
| Q1 25 | 27.5% | 16.9% | ||
| Q4 24 | 21.6% | 20.5% | ||
| Q3 24 | 24.7% | 18.4% | ||
| Q2 24 | 22.8% | 19.7% | ||
| Q1 24 | 20.7% | 20.0% |
资本支出强度BILLRVTY
| Q4 25 | 0.4% | 2.6% | ||
| Q3 25 | 0.3% | 2.6% | ||
| Q2 25 | 0.7% | 2.6% | ||
| Q1 25 | 0.3% | 2.4% | ||
| Q4 24 | 0.1% | 3.4% | ||
| Q3 24 | 0.0% | 3.3% | ||
| Q2 24 | 0.1% | 3.2% | ||
| Q1 24 | 0.0% | 2.7% |
现金转化率BILLRVTY
| Q4 25 | — | 1.85× | ||
| Q3 25 | — | 2.97× | ||
| Q2 25 | — | 2.49× | ||
| Q1 25 | — | 3.03× | ||
| Q4 24 | 2.35× | 1.84× | ||
| Q3 24 | 9.94× | 1.57× | ||
| Q2 24 | 10.35× | 2.87× | ||
| Q1 24 | 2.10× | 5.67× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
BILL
| Accounts Payable And Accounts Receivable Solutions | $185.9M | 45% |
| Spend And Expense Interchange Revenue | $166.5M | 40% |
| Interest On Funds Held For Customers | $39.5M | 10% |
| Embedded And Other Solutions | $22.8M | 5% |
RVTY
| Immunodiagnostics | $240.8M | 31% |
| Life Sciences | $191.4M | 25% |
| Reproductive Health | $149.3M | 19% |
| Segment Operating Income | $132.0M | 17% |
| Software | $62.3M | 8% |
